spacer
home > epc > autumn 2002 > cro selection - a process revisited
PUBLICATIONS
European Pharmaceutical Contractor

CRO Selection - A Process Revisited

Outsourcing of clinical activities has become a complex and expensive business with inherent risks that could, if continued in a haphazard manner, lead to the squandering of resources, both in terms of money, product registration time and personnel time. The tactical (on an individual project basis) and isolationist (limited involvement of functional groups) nature of the approaches by pharmaceutical companies toward clinical outsourcing may reduce the value that they derive from the process.

This article aims to look at the core processes involved in the selection of a CRO partner, whether a sponsor decides to approach the process in a tactical or a strategic manner. The article will describe and suggest how best to structure the sponsor's outsourcing teams to maximise the returns on investment. There should be a focus on quality in the selection process. Quality will then dictate the acceptable price. The current focus is on price, which has produced variable quality in terms of contractual delivery and regulatory acceptability.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Sherif Odaranile, Clinical Auditor at ADAMAS Consulting

Sherif Odaranile obtained a BSc in Biomedical Sciences from Portsmouth School of Pharmacy in 1988. He qualified as an MLSO at the Queen Alexandra Hospital in Cosham before joining Eli Lilly in 1990 as a Medical Representative.

He moved on to E Merck-Lipha Pharmaceuticals initially as a Senior Medical Representative before switching to the clinical arena as a Clinical Research Associate in 1994. Sherif worked in the CNS and rheumatology areas as a Monitor and then as a Project Co-ordinator. He developed an interest in clinical contracts and outsourcing which led to roles as Contracts Manager and Business Analyst at SmithKline Beecham and Biogen Ltd between 1998 and 2001. Sherif joined ADAMAS Consulting in November 2001.


spacer
Sherif Odaranile
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics expands into additional facility at Granta Park in Cambridge, UK

New offices at leading science hub support the Company’s rapid growth following recent investment New facility is in addition to headquarters at Babraham Research Campus, Cambridgeshire, UK and offices in Monmouth Junction, New Jersey, USA
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement